Abnova (Taiwan) Corporation (TPE:4133)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.10
+0.35 (1.26%)
Jul 25, 2025, 1:35 PM CST
1.26%
Market Cap1.70B
Revenue (ttm)360.75M
Net Income (ttm)48.51M
Shares Out60.55M
EPS (ttm)0.80
PE Ratio35.12
Forward PEn/a
Dividend0.90 (3.24%)
Ex-Dividend DateJun 16, 2025
Volume212,557
Average Volume112,076
Open27.80
Previous Close27.75
Day's Range27.80 - 28.40
52-Week Range21.70 - 35.10
Beta0.14
RSI57.57
Earnings DateAug 8, 2025

About Abnova (Taiwan)

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 4133
Full Company Profile

Financial Performance

In 2024, Abnova (Taiwan)'s revenue was 355.26 million, a decrease of -7.01% compared to the previous year's 382.05 million. Earnings were 61.61 million, an increase of 41.05%.

Financial Statements

News

There is no news available yet.